Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07989468
ABSTRACT:
The present invention relates to SNS-595 and methods of treating cancer using the same.
REFERENCES:
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5817669 (1998-10-01), Tomita et al.
patent: 2003/0216316 (2003-11-01), Haran-Ghera et al.
patent: 2008/0063642 (2008-03-01), Adelman et al.
patent: 09-221424 (1997-08-01), None
patent: 11-349565 (1999-12-01), None
patent: WO 01/74395 (2001-10-01), None
patent: WO2005/089756 (2005-09-01), None
patent: WO 2007/028171 (2007-03-01), None
patent: WO 2007/146335 (2007-12-01), None
patent: WO 2008/016678 (2008-02-01), None
patent: WO 2009/054935 (2009-04-01), None
patent: WO 2009/075841 (2009-06-01), None
The Oxford Textbook of Oncology, 1995, vol. 1, Oxford University Press, pp. 445-452.
Freireich et al. Cancer Chemotherapy Reports, 1966, vol. 50, No. 4, pp. 219-244.
Rustum et al. Pharmac. Ther., 1992, vol. 56, pp. 307-321.
Tomitra, Kyoji Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1.4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1, J. Med. Chem. 2002, vol. 45, pp. 5564-5575, 2002.
Tsuzuki, Yasunori et al., “Efficient stereospecific synthesis of (S,S)-3-methoxy-4-methylaminopyrrolidine”, Tetrahedron: Asymmetry, vol. 12, pp. 1793-1799, 2001.
Tsuzuki, Yasunori et al., Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 2, vol. 47, pp. 2097-2109, 2004.
Patrick Therasse, et al. “New Guidelines to Evaluate the Response toTreatment in Solid Tumors”, Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000.
K. Tomtia, et al., Database CAPLUS Accession No: 1999:92763, “Synthesis and Antitumor activity of Novel 7-Substituted 1, 4-dihydro-4-oxo-1-2(2-thiazolyl)-1, 8-naphthyridine-3-carobxylic Acids”, BK Abstracts, 217thACS Nat Mtg., Mar. 21-25, 1999.
Shigeki Kashimoto, et al., Database BIOSIS Accession No: 2001:366681, “Antitumor Activity of a Novel Quinolone Analog AG-7352 in Human Xenograft Models of Leukemia or Drug-Resistant Tumors and in an Experimental Metastatic Tumor Model”, Proc. Am. Assoc. Can. Res. An. Mtg., vol. 42, p. 102, Mar. 2001.
T.S. Herman, et al., Database MEDLINE Accession No: 78104303,“Nabilone: A Potent Antiemetic Cannabinol with Minimal Euphoria”, Biomedicine, vol. 27, No. 9-10, pp. 331-334, Dec. 1977.
J.C. Allen, Database MEDLINE Accession No. 92345081, “Complications of Chemotherapy in Patients with Brain and Spinal Cord Tumors”, Ped. Neurosurg., vol. 17, No. 4, pp. 218-224, 1991-1992.
B. Ryffel, Database CANCERLIT Accession No. 97254190, “Safety of Human Recombinant Proteins”, Biomed. Environ. Sci. vol. 10, No. 1, pp. 65-72, Mar. 1997.
J. Glaspy, et al., Database CANCERLIT Accession No. 2002-047630, “A Dose-Finding and Safety Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Patients Receiving Multicycle Chemotherapy”, Br. J. Cancer, vol. 84 (Suppl. 1), pp. 17-23, Apr. 2001.
Anthony W. Tolcher, et al., “Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog with Topoisomerase Inhibitory Properties”, Journal of Clinical Oncology, vol. 19, No. 11, Jun. 1, 2001.
Chiba, et al., “Practical Synthesis of AG-7352, Optically Active New Antitumor Agent.” Abstract, 218thACS National Meeting, Aug. 22-26, 1999.
Evanchik, et al., “Non-Clinical Admet, PK, and Biological Activity of SNS-595, a Novel Cell Cycle Inhibitory Antineoplastic Agent.” Drug metabolism reviews, Marcel Dekker,New York, NY, US, vol. 36, No. SUPPL1, Aug. 2004 (2004-2008), p. 103. XP008073741.
Lawrence, et al., “SNS-595, a Novel S-Phase Active Cytotoxic, Demonstrates Pharmacologic Properties Appropriate for the Treatment of Advanced Hematologic Malignancies.” Blood, vol. 106, No. 11, Part 2, Nov. 2005, p. 2378. XP008073743.
Lawrence, et al., “SNS-595, A Novel S-Phase Active Cytotoxic, Exhibits Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Advanced Hematoloic Malignacies.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 47, Apr. 2006, p. 1110. XP001199684.
Nakano, et al., “Antitumor Activity of a Novel Quinolone DNA Topoisomerase II Inhibitor AG-7352.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 40, Mar. 1999, p. 115-Abstract 767. XP008073720.
Sato, et al., “In Vivo Antitumor Activity of a Novel Quinolone Analogue AG-7352 Against a Borad-Spectrum of Cancers and Drug-Resistant Human Cancers.” Abstract, 11thNCI-EOARTC-AACR symposium on new drugs in cancer therapy, Nov. 7-10, 2000.
Tsuzuki, et al., “Practical Synthesis of (3S,4S)-3-Methoxy-4-Methylaminopyrrolidine.” Tetrahedron: Asymmetry 12(2001) 2989-2997.
Tsuzuki, et al., “Process Research of a Novel Quinolone Antitumor Agent, AG-7352.” English Abstract, The Japanese Society for Process Chemstry, 2004 Summer Symposium.
Tsuzuki, et al., “Synthesis and Structure—Activity Relationships of 3-Substitued 1, 4-Dihydro-4-Oxo-1-(2-Thiazolyl)-1, 8-Naphthridines as Novel Antitumor Agents.” Bioorganic & Medicinal Chemistry Letters 14 (2004): 3189-3193.
Tsuzuki, et al., “Synthesis of Optically Active Amine at C-7 Position of New Antitumor Agent AG-7352.” Abstract, Molecular Chirality Conference, 1999.
Wright, et al., “SNS-595 Has Synergistic Activity in Vitro with DNA Damaging Agents and Antimetabolites.” Proceddings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 47, Apr. 2006, p. 504.
Adelman Daniel C.
Silverman Jeffrey A.
Anderson James
Jones Day
Sunesis Pharmaceuticals, Inc.
LandOfFree
Methods of using SNS-595 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using SNS-595, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using SNS-595 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777846